Fertility-sparing treatment in young women with endometrial cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This study follows young women who had fertility-sparing treatment for endometrial cancer or a precancerous condition. It aims to understand how the treatment affects cancer outcomes, future fertility, and quality of life over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had fertility-sparing treatment for endometrial cancer or a precancerous condition called endometrial intraepithelial hyperplasia (EIN).
- You are between 18 and 45 years old.
- You are treated at a hospital in Sweden that is part of this study.
- Your treatment is planned between January 2025 and January 2028.
- You speak English or Swedish.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at combining genetic testing with surgical exams to better understand endometrial cancer. It may help doctors see which treatments could work best for you.
This trial tests a tailored approach to preserve fertility in women with early-stage endometrial cancer, using medications like hormones and immunotherapy based on the tumor's molecular subtype. It aims to avoid hysterectomy and keep the uterus intact.
This study looks at whether a hormone-releasing IUD (LNG-IUS) can treat early-stage endometrial cancer or very early abnormal cell growth while helping you keep the option for future pregnancy. It aims to see how well the treatment works and how it affects fertility-related outcomes.
This trial studies whether removing an early, hormone-responsive uterine growth using a procedure through the cervix can keep fertility possible. It is for people under 40 with a specific low-risk uterine biopsy and MRI findings who have already tried hormone treatment.
This study looks at how people with endometrial cancer manage their care and treatment. It aims to understand your experiences to help improve support for others.
This trial tests a combination of an immunotherapy drug (TQB2450) with a hormone treatment (progestin) for patients with a specific type of early-stage uterine cancer who wish to preserve their ability to have children. The goal is to see if this approach is safe and effective.
Hear when a new Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.